



# Data Transparency Conference

Demystifying Clinical Data Transparency:  
Lessons learnt so far.



12-13 FEB 2019



BIP, Rue Royale 2-4,  
1000 Brussels, Belgium

## Conference Programme

Event Sponsor:



European Federation of Pharmaceutical  
Industries and Associations

Supported by:





# DAY 1: full programme

08h00 - 08h45	Registration
08h45 - 09h00	Conference Opening
09h00 - 10h15	<b>Session 1: Regulatory Aspects &amp; Updates</b>
	<b>a. Overall introduction</b> Speaker: Dr. Christopher Marshallsay, Grünenthal GmbH
	<b>b. Update from EFPIA: reporting on how often data are being shared</b> Speaker: Sini Eskola, EFPIA
10h15 - 10h45	Break
10h45 - 13h00	<b>Session 2: Regulatory Aspects &amp; Updates</b>
	<b>a. Use of Clinical Trial Data in HTA – The IQWiG Perspective</b> Speaker: Dr. Cornelia Rüdiger, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
	<b>b. Compliance with EU CTR, MDR and GDPR and how it impacts Data Transparency</b> Speaker: An Vijverman, Dewallens & Partners
	<b>c. Data protection in reality</b> Speaker: Isabelle Huys, KU Leuven
	<b>d. Point of view of the regulator</b> Speaker: Pieter Vankeerberghen, FAMHP
	<b>e. Wrap up morning session &amp; Q&amp;A</b>
13h00 - 14h00	Lunch
14h00 - 15h30	<b>Session 3: How are the rules lived</b>
	<b>a. Watchdog initiative</b> Speaker: Thomas Wicks, TrialScope, Inc.
	<b>b. Clinical Data Transparency: Data use from an academic perspective</b> Speakers: Sarah Lehmann, Technische Hochschule Köln
	<b>c. Defining rules from an academic perspective</b> Speaker: Prof. Frank Rademakers, UZ Leuven
15h30 - 16h00	Break
16h00 - 17h15	<b>Session 4: Pro-active Approach</b>
	<b>a. Smart authoring of CSRs to reduce extra work during data sharing</b> Speakers: Tracy Farrow, PPD & Sam Hamilton, Sam Hamilton Medical Writing Services Limited
	<b>b. Practical challenges when implementing Data Transparency</b> Speaker: Dr. Christopher Marshallsay, Grünenthal GmbH
	<b>c. Q&amp;A and Closing remarks Day 1</b>
18h00	Dinner

# DAY 2: full programme



08h00 - 08h30	Welcome Coffee
08h30 - 10h30	<b>Session 5: Anonymisation</b> <b>a. SHADOW: An Integrated Data and Document De-Identification Solution</b> Speaker: Thomas Kalfas, GCE Solutions <b>b. Implementing Policy 0070 and lessons learned from preparing 3 dossiers for publication</b> Speaker: Dr. Sybille Eibert, Teva Pharmaceuticals International GmbH <b>c. "Case Study: Experience implementing Policy 070 Experience with unexpected data transparency"</b> Speaker: Sascha Seidl, Merck <b>d. Case Study: Experience implementing anonymisation</b> Prof. Joris Vermeesch, UZ Leuven
10h30 - 11h00	Break
11h00 - 13h00	<b>Session 6: Workshop around anonymisation</b> <b>a. Introduction to the anonymisation &amp; redaction of documents</b> Speaker: Tracy Farrow, PPD <b>b. Exercise - Redaction of a subject narrative</b> Speaker: Tracy Farrow, PPD <b>c. Posting of redacted protocols and statistical analysis plans on ClinicalTrials.gov</b> Speaker: Sybille Eibert, TEVA <b>d. Wrap up morning session &amp; Q&amp;A</b>
13h00 - 14h00	Lunch
14h00 - 15h30	<b>Session 7: The future of Data Transparency - Panel discussion</b> <b>a. The future of Data Transparency?</b> Speaker: Christopher Marshallsay, Grünenthal GmbH <b>b. Panel Discussion with Representatives from pharma, biotech, academic, regulators, legal</b> Speakers: Tracy Farrow, Dr. Christopher Marshallsay, Sybille Eibert, Sascha Seidl
15h30 - 16h00	Closing Remarks

# EFPIA SPONSORSHIP

#WeWontRest Campaign

## ILLNESS NEVER SLEEPS SO NEITHER DO WE

By working together we want to get innovative health solutions to patients across Europe and make Europe a world leader in medical research and development

Find out more about the research-based pharmaceutical industry's manifesto for a brighter tomorrow at [www.efpia.eu/manifesto](http://www.efpia.eu/manifesto)

#WeWontRest **efpia**

From the research-based pharmaceutical industry in Europe

Beyond being required by law, data transparency in clinical trials is also an ethical and business critical aspect of drug development. Data Transparency is important to reduce avoidable burden on and/or risk to trial subjects due to the avoidance of unwarranted trial repetition, enable data-driven decisions by healthcare professionals, regulators, price selection, and pharmaceutical companies, and finally to ensure unbiased reporting of clinical trials. Throughout this Conference, we will tackle data transparency from different angles with experts from the field.

### **3 Key objectives for this Conference:**

1. Enable a realistic assessment of what is required, and how these requirements could be met
2. Share information with peers as this topic is complex and dynamic and it is hard to be up-to-date on all developments
3. Establish and facilitate contacts between different players of the industry, the academic world, regulators and service providers

**Register at [www.ec crt.com](http://www.ec crt.com)**